Effect of a Recombinant Human Soluble Thrombomodulin on Baseline Coagulation Biomarker Levels and Mortality Outcome in Patients With Sepsis-Associated Coagulopathy. Issue 8 (August 2020)

• Record Type: Journal Article
• Authors: Levi, Marcel; Vincent, Jean-Louis; Tanaka, Kosuke; Radford, Amanda H.; Kayanoki, Toshihiko; Fineberg, David A.; Hoppensteadt, Debra; Fareed, Jawed
• Is Part Of: Critical care medicine. Volume 48:Issue 8(2020)
• Publication Date: 2020-08
• Subjects: international normalized ratio -- platelet count -- prothrombin fragment 1.2 -- recombinant human soluble thrombomodulin -- sepsis -- thrombin-antithrombin complex; Critical care medicine -- Periodicals; Soins intensifs -- Périodiques; 616.028
• DOI: 10.1097/CCM.0000000000004426
• Languages: English
• ISSNs: 0090-3493

Abstract

Abstract : Objectives: To assess the effects of recombinant human soluble thrombomodulin treatment on 28-day all-cause mortality in subgroups categorized by baseline coagulation biomarker levels (prothrombin fragment 1.2, thrombin-antithrombin complex, D-dimer) in patients with sepsis-associated coagulopathy in the Sepsis Coagulopathy Asahi Recombinant LE Thrombomodulin trial (SCARLET) (NCT01598831). Design: Post hoc, subgroup analysis of a randomized, double-blind, placebo-controlled, multinational, multicenter phase 3 study. Setting: ICUs at 159 sites in 26 countries. Patients: Eight-hundred adults with sepsis-associated coagulopathy defined as international normalized ratio greater than 1.40 and platelet count between 30 × 10 9 /L and 150 × 10 9 /L or greater than 30% decrease within 24 hours with concomitant cardiovascular and/or respiratory failure. Interventions: Patients randomized and treated with recombinant human soluble thrombomodulin (0.06 mg/kg/d; n = 395) or equivalent placebo ( n = 405) for 6 days. Measurements and Main Results: Recombinant human soluble thrombomodulin did not significantly reduce 28-day all-cause mortality in the Sepsis Coagulopathy Asahi Recombinant LE Thrombomodulin trial: absolute risk reduction was 2.55% ( p = 0.32) in patients with sepsis-associated coagulopathy. In this post hoc analysis, mortality steadily increased with increasing baseline prothrombin fragment 1.2 and thrombin-antithrombin complex levels in the placebo group; for those values exceeding the upper limit of normal, the mortality increases in the recombinant human soluble thrombomodulin group were lower or negligible with increasing baseline prothrombin fragment 1.2 and thrombin-antithrombin complex. Consequently, absolute risk reductions were greater in subgroups with higher baseline prothrombin fragment 1.2 or thrombin-antithrombin complex. Absolute risk reductions were also greater in subgroups with baseline coagulation biomarker levels at or above median of the entire study population, ranging from 4.2% (95% CI, –5.0% to 13.4%) to 5.5% (95% CI, –4.0% to 14.9%). Conclusions: Compared with patients receiving placebo, patients treated with recombinant human soluble thrombomodulin having higher baseline thrombin generation biomarker levels had lower mortality. Further research regarding the predictive role of coagulation biomarkers for recombinant human soluble thrombomodulin treatment response in sepsis-associated coagulopathy is warranted to evaluate clinical relevance.